Next Article in Journal
Behavior of Male Gamete Fusogen GCS1/HAP2 and the Regulation in Arabidopsis Double Fertilization
Next Article in Special Issue
Design, Synthesis and Biological Evaluation of Quinazolinamine Derivatives as Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors with Improved Metabolic Stability
Previous Article in Journal
Prognostic Biomarker SPOCD1 and Its Correlation with Immune Infiltrates in Colorectal Cancer
Previous Article in Special Issue
Prognostic Impacts of LL-37 in Relation to Lipid Profiles of Patients with Myocardial Infarction: A Prospective Cohort Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 13
Issue 2
10.3390/biom13020210
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer

by
Zhenfang Du
1,*,
Jinghan Sun
2,
Yunkai Zhang
3,
Nigaerayi Hesilaiti
1,
Qi Xia
1,
Heqing Cui
4,
Na Fan
5 and
Xiaofang Xu
6
1
Department of Genetic and Developmental Biology, School of Medicine, Southeast University, Nanjing 210003, China
2
School of Life Science and Technology, Southeast University, Nanjing 210018, China
3
BioSpatula LLC, Telford, PA 18969, USA
4
Department of Radiotherapy, Nanjing Chest Hospital, Nanjing Medical University Affiliated Brain Hospital, Nanjing 210029, China
5
Department of Respiratory Medicine and Critical Care Medicine, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China
6
Department of Thoracic Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China
*
Author to whom correspondence should be addressed.
Biomolecules 2023, 13(2), 210; https://doi.org/10.3390/biom13020210
Submission received: 30 November 2022 / Revised: 9 January 2023 / Accepted: 11 January 2023 / Published: 20 January 2023
(This article belongs to the Special Issue Biomarkers and Therapeutical Targets in Precision Medicine)
Browse Figures
Review Reports Versions Notes

Abstract

:
Oncogenic mutations within the EGFR kinase domain are well-established driver mutations in non–small cell lung cancer (NSCLC). Small-molecule tyrosine kinase inhibitors (TKIs) specifically targeting these mutations have improved treatment outcomes for patients with this subtype of NSCLC. The selectivity of these targeted agents is based on the location of the mutations within the exons of the EGFR gene, and grouping mutations based on structural similarities has proved a useful tool for conceptualizing the heterogeneity of TKI response. Structure-based analysis of EGFR mutations has influenced TKI development, and improved structural understanding will inform continued therapeutic development and further improve patient outcomes. In this review, we summarize recent progress on targeted therapy strategies for patients with EGFR-mutant NSCLC based on structure and function analysis.

1. Introduction

Lung cancer is the most common cause of cancer-related death worldwide, accounting for 21.5% of male and 13.7% of female deaths from cancer in 2020 [1]. Histologically, 85% of patients with lung cancer can be classified with non–small cell lung cancer (NSCLC). Mutations within the epidermal growth factor receptor (EGFR) kinase domain are the root cause of a subtype of NSCLC and account for up to 50% of NSCLC, depending on demography [2,3,4,5], with higher proportions observed in females (42% of diagnoses) [6], east Asians (47% of diagnoses) [4], and nonsmokers (30.6% of diagnoses) [7]. The administration of small-molecule tyrosine kinase inhibitors (TKIs) specifically targeting mutant EGFR has made considerable progress in the treatment of this subset of patients compared with conventional chemotherapy [8,9,10,11].
In normal human physiology, the epidermal growth factor ligand binds to the extracellular domain of EGFR and induces conformational alterations [12,13,14]. These alterations release the autoinhibition of the basal state [15] and drive the asymmetric dimerization of intracellular kinase domains, in which one kinase domain acts as activator (“donor”) and the other as receiver (“acceptor”). The kinase domains of the asymmetric dimer phosphorylate the C-terminals of each other in a trans manner and transmit the signal from extracellular to intracellular [16]. Asymmetric dimers finally undergo multimerization, or higher-order oligomerization, in the manner of a “head-to-tail” chain [17,18]. Different ligands bind to EGFR and induce varying receptor conformations, which subsequently leads to differential downstream signaling [19]. Oncogenic mutations within the EGFR kinase domain lead to constitutive activation of the receptor and its downstream signaling, which promotes cell survival and proliferation [20,21,22,23,24]. Small-molecule TKIs reversibly or irreversibly bind the ATP pocket of the EGFR kinase domain and inhibit receptor autophosphorylation and downstream signaling [20,25].
TKI sensitivity can be classified based on the distribution of mutations within the exons of the EGFR gene [26]. The majority of EGFR mutations are classical mutations, including the canonical exon 19 deletions (Ex19Del) and the L858R point mutation in exon 21, which together account for up to 90% of all EGFR mutations and confer sensitivity to EGFR TKIs [27]. (Note: In this review, we use the most common EGFR protein nomenclature, which includes numbering a 24-residue sequence found in immature EGFR; thus, for example, we will use L858R instead of L834R). The remaining EGFR mutations (those that are not Ex19Del or L858R) are uncommon or rare mutations with variable TKI sensitivity [28]. Mutations within exons 18, 19 and 21 are sensitive (e.g., G719X, L747P and L861Q, correspondingly) [29,30,31,32,33,34,35,36], while most exon 20 mutations are insensitive to EGFR TKIs (e.g., most exon 20 insertions) [37,38,39,40,41]. Exceptionally, S768I is an exon 20 mutation sensitive to first- and third-generation EGFR TKIs [42], though less so than the canonical L858R mutation [43]. A763_Y764insFQEA, one of the exon 20 insertions, is located in the middle of the αC helix. The FQEA insertion shifts the register of the αC helix toward its N terminus, resulting in a longer β3–αC loop and activating the receptor by destabilizing the inactive conformation in a related manner to the classical mutation L858R [21,44]. Therefore, differently from other exon 20 insertions, A763_Y764insFQEA confers sensitivity to first-, second- and third-generation EGFR TKIs [45]. The discordance within these traditional exon-based groupings demonstrates the shortcomings of this conceptual framework.
Structural studies have improved our understandings of EGFR biology and TKI sensitivity, and are a powerful tool in EGFR TKI drug discovery [27,46,47,48]. Using hierarchical clustering of TKI selectivity and mutational mapping, Robichaux et al. classified EGFR kinase domain mutations into four distinct subtypes: (1) classical-like mutations that are far from the ATP-binding pocket; (2) T790M-like mutations that are located in the hydrophobic core; (3) exon 20 insertions in the αC–β4 Loop following the C-terminal end of the αC-helix (Ex20ins-L); (4) P-loop and αC-helix compressing (PACC) mutations that are located on the interior surface of the ATP-binding pocket or C-terminal portion of the αC-helix. This structure-based classification has proved a better framework for categorizing mutations by TKI sensitivity and patient outcomes than previous exon-based grouping [27]. In this review, we primarily discuss the TKI sensitivity and selectivity for “classical” EGFR mutations and uncommon mutations based on structure and function studies.

2. The Conformational States of EGFR Kinase Domain

The EGFR kinase domain consists of the N-lobe and C-lobe with the ATP-binding site connecting the two lobes. The N-lobe is mainly formed of β-strands (β1-β5), the regulatory αC-helix and the glycine-rich phosphate-binding loop (P loop), whereas the larger C-lobe mainly consists of helices, with a conformationally variable activation loop (A loop). In the absence of ligand, the receptor predominantly exists as a monomer, with the kinase domains in inactive conformation [14]. In “Src-like inactive” conformation, the αC-helix is rotated outward (the “αC-out” conformation) and is maintained by a two-turn helix within the N-terminal portion of the A loop [16]. The catalytically important KE salt-bridge interaction between Lys745 and Glu762 is disrupted, while the Glu762-Lys860 salt bridge is formed [49]. Leu858 and Leu861 pack towards the αC helix, preventing the formation of the Lys745-Glu762 salt bridge (Figure 1A). In the presence of ligand, the receptors form dimers and multimers or higher-order oligomers, in which the kinase domains switch to active conformation [13]. In this conformation, the αC helix is rotated inwards the ATP-binding site (the “αC-in” conformation). The A loop maintains the β9 strand and forms an overall conformation well accommodating the substrate binding. The Lys745-Glu762 salt bridge is formed, and Leu858 and Leu861 are surface-exposed [16] (Figure 1B). In addition, during the transition from the active to “Src-like inactive” conformation, the intrinsically disordered conformation has been observed and featured the αC helix partially disordered and placed “out,” while the A loop maintains the β9 strand intact like in active conformation [21].

3. Targeted Therapy for NSCLC Patients with EGFR Mutations

Multiple targeted agents, including first-, second- and third-generation EGFR TKIs, have been approved or are under active investigation for patients with EGFR-mutant NSCLC (Table 1). The first-generation TKIs, including erlotinib and gefitinib, are reversible inhibitors, binding both to mutant as well as wild-type (WT) EGFR [9,10]. The second-generation TKIs, including afatinib and dacomitinib, are irreversible inhibitors that covalently bind to EGFR [28,50]. The third-generation EGFR TKIs, including osimertinib (AZD9291), aumolertinib (HS-10296) and alflutinib (AST2818), are irreversible inhibitors that selectively bind to mutant EGFR and show greater efficacy than the first- and second-generation TKIs [51]. Osimertinib has been approved by the FDA for both frontline and second-line treatment of NSCLC with EGFR-sensitizing mutations [52,53,54]. Aumolertinib (HS-10296) and alflutinib (AST2818) have been approved for the treatment of EGFR-mutant NSCLC in China [55,56,57]. Acquired resistance inevitably occurs, and a promising new generation of EGFR-targeting agents is under investigation [58,59].

3.1. Classical Mutations

We analyzed the GENIE lung cancer dataset (GENIE Cohort v12.0-public, n = 153,834) [60] and found that Ex19Del and L858R are found in 71.9% of NSCLCs with an EGFR mutation. Ex19Del and L858R are the sole EGFR mutations in 34.3% and 28.5%, respectively, while co-occurrence of Ex19Del or L858R with uncommon EGFR mutations accounts for 6.0% and 3.1% of cases (Figure 2a). Ex19Del and L858R as classical mutations confer sensitivity to all first-, second- and third-generation EGFR TKIs [10,20,22,55,56,61,62] (Figure 3), and co-occurrence of an uncommon mutation does not impact TKI sensitivity [40,63]. In fact, patients with complex “classical” mutations (Ex19Del or L858R in complex with an uncommon EGFR mutation) might have more favorable clinical outcomes than patients with uncommon mutations alone [64,65]. We have not found any classical + classical complex mutations in our analysis of GENIE dataset. The sensitivity of this class of complex mutations might be equivalent to the corresponding single mutation, as L858R + Ex19Del complex mutations display similar patient outcomes with EGFR TKI treatment compared to patients with single classical mutations alone [66].
Structurally, Leu858 lies within the two-turn helix of the A loop and packs against the αC helix in the “Src-like inactive” conformation. Arginine has a much larger side chain than leucine, and substitution of Leu858 with arginine is not tolerated with the inactive conformation [20]. The positively charged Arg858 is surrounded by a cluster of negatively charged residues (Glu758, Asp855, and Asp837), which stabilize the αC helix and the KE salt bridge. Therefore, the substitution holds the kinase domain in the active conformation likely at the expense of locally disordered conformation, rather than “Src-like inactive” conformation [21] (Figure 1). As a result, L858R mutation promotes the ligand-independent dimerization of EGFR kinase [24]. Structure-based approaches classify L858R into classical-like mutations, as Arg858 is located at the N-terminal portion of the A loop in the C-lobe, which is far from the ATP-binding pocket [27]. A spectrum of rare L858R + mutations were also categorized into classical-like mutations [27]. This subgroup of mutations is sensitive to all first-, second- and third-generation EGFR TKIs (Figure 4).
Ex19Del mutations shorten the length of β3-αC loop and suppress the locally disordered conformation [21], and therefore constrain the αC helix to the active conformation [22], with the KE salt bridge making the interaction between the kinase domain and ATP favorable [67]. There have been more than 20 Ex19Del variants identified in NSCLC [68]. The length of the β3–αC loop functions as a rheostat for kinase activity. Specifically, deletion of five amino acids (E746_A760) makes an optimal orientation of the αC helix for catalytic activity, while other deletions also result in structural perturbations of the αC helix that impair kinase activity compared to WT EGFR [22]. This conformational difference leads to variable ability to form ligand-independent dimerization and therefore differential sensitivity to EGFR TKIs [68,69]. Clinically, variations in Ex19Del are translated into differential clinical features and treatment outcomes [70]. Ex19Del mutations were classified into classical-like mutations as, structurally, the β3–αC loop in the N-lobe is far from the ATP-binding pocket [27]. A spectrum of Ex19Del + rare mutations were also categorized into classical-like mutations (Figure 4).
Ex19Del and L858R mutants have a lower competitive binding affinity for ATP than WT EGFR. First-generation EGFR TKIs bind more favorably to the kinase domain of mutants than WT, thereby inhibiting mutant kinase activities in a therapeutically useful manner [20]. The substitution of Thr790 to the bulky methionine increases the ATP affinity and stabilizes the active conformation of EGFR kinase domain, which sterically prevents the binding of first-generation TKIs, thereby imparting drug resistance [71]. Second-generation TKIs bind irreversibly to EGFR Cys797 at the margin of the ATP-binding cleft by covalent adduct formation, and were anticipated to overcome acquired resistance caused by T790M mutation [72]. However, the poor selectivity of second-generation TKIs for T790M over WT EGFR results in dose-limiting toxicities that limit clinical efficacy [61]. Osimertinib has a differential binding pose with Met790 from Thr790 of WT EGFR, thus yielding greater selectivity for T790M mutation over WT EGFR than afatinib [25]. Greater selectivity has translated into more favorable treatment outcomes, as either second-line or first-line therapy, than earlier-generation EGFR TKIs [52,53].

3.2. Uncommon EGFR Mutations

3.2.1. Exon 18 Mutations

EGFR exon 18 mutations include E709_T710insX (e.g., exon 18 deletion, Ex18Del), E709X and G719X (Figure 2b). From our analysis of the GENIE dataset, either E709X or E709-T710insX as a single EGFR mutation accounts for around 0.68% of all EGFR mutations and 1.7% of rare EGFR mutations in NSCLC (data not shown). Around 96% of E709X co-occurs with another EGFR mutation, such as G719X or L861X (Table S3 and S9). G719X mutations as independent EGFR mutations, including G719A, G719C, G719S, G719D and G719V, and account for 4.0% of rare EGFR mutations and 1.6% of all EGFR mutations in NSCLC. G719X mutations also co-occur with other EGFR mutations, which represent 8.4% of rare EGFR mutations and 3.2% of all EGFR mutations in NSCLC (Figure 2c).
Preclinical studies show that exon 18 mutations including E709K, E709_T710insD and G719A are sensitive to first-, second- and third-generation EGFR TKIs, but show less sensitivity than Ex19Del [39] (Figure 3). Exon18 mutations tend to be more sensitive to second-generation TKIs than first- and third-generation EGFR TKIs [40,68,69]. E709K and G719A tend to be more sensitive to EGFR TKIs than E709-T710insD [40,68]. Clinically, patients with G719X and Ex18Del respond poorly to first-generation TKIs [39], and patients with G719X also respond poorly to the third-generation TKI osimertinib [70]. Few clinical data about second- and third-generation TKIs exist for E709X as a single EGFR mutation.
Both Glu709 and Gly719 are located in the N-lobe. Glu709 is located on the N-terminal end of the β1 strand, which is immediately followed by the P loop. Gly719 is the first glycine in the evolutionarily conserved “GXGXXG” motif of the P loop. Substitution of Gly719 to non-glycine residues decreases the flexibility of the P loop and attenuates the hydrophobic interactions that constrain the αC-helix in the inactive conformation [20]. Therefore, G719X mutations destabilize the inactive conformation and are well accommodated in the active conformation [20,21]. This conformation increases the propensity for dimerization and subsequent receptor activation. Exon 18 mutations, including E709X, G719X and Ex18Del mutations, were categorized as PACC mutations [27] (Figure 4). Structurally, PACC mutations change the flexibility of the P loop and destabilize an osimertinib-binding pattern. By contrast, second-generation TKIs do not interact with the P loop and favor the binding pose. Therefore, PACC mutations are more sensitive to the second-generation TKIs than other-generation TKIs [27]. Clinically, patients with G719X mutations are more responsive to second-generation EGFR TKIs than first- and third-generation TKIs [42,72,73]. Similarly, patients who develop resistance to osimertinib via a mutation in Gly724, the third glycine in the “GXGXXG” motif, often respond to second-generation EGFR TKIs [74,75,76,77], but not first-generation TKIs [78]. The variable sensitivity of different exon 18 mutations observed in previous studies might be explained by the differential flexibility of the P loop induced by mutations.

3.2.2. Exon 19 Mutations

We found 13 cases with L747P mutation in the GENIE dataset. We also found 5 cases with L747X complex mutations, including L747F + L861Q (1 case), L747S + G719C (2 cases) and L747A + I744M (2 cases). We have not found exon 19 insertions in the GENIE dataset, while this subset of mutations has been reported to account for approximately 1% of EGFR-mutant NSCLC [63]. Available clinical data indicate that L747P/S mutations are resistant to first- and third-generation EGFR TKIs [79,80] and confer sensitivity to second-generation EGFR TKIs [81,82]. Consistent with this evidence, L747X mutations were included in PACC mutations, as substitution of Leu747 to proline or serine might alter the rigidity of the β3–αC loop, which stabilizes the αC-helix and KE salt bridge interactions in the active conformation [83].

3.2.3. Exon 20 Mutations

EGFR exon 20 insertion (Ex20ins) mutations contain a broad spectrum of small insertions of 1–7 amino acids that occur within the C-terminal end of the αC-helix and the immediately following loop [37]. After classical mutations, Ex20ins mutations are the next most prevalent EGFR mutation in NSCLC [84]. From the GENIE dataset, we found more than 60 different forms of Ex20ins mutations, accounting for 16% of rare EGFR mutations and 6.2% of all EGFR mutations in NSCLC (Figure 2). We also found other forms of exon 20 mutations, including S768I (3 cases), V774L (1 case) and Q787L (1 case) (Figure 3). Exon 20 mutations also co-occur with other EGFR mutations (Figure 2c).
Variable TKI sensitivity has been found in different types of Ex20ins mutations [85,86]. Most patients harboring Ex20ins mutations are insensitive to most of the FDA-approved EGFR TKIs [87,88,89,90]. However, a specific subset of insertions within the C-terminal portion of the αC-helix, for example, A763_Y764insFQEA, are sensitive to first-generation EGFR TKIs [44]. Multiple reports have demonstrated A763_Y764insFQEA is also responsive to second- and third-generation EGFR TKIs with comparable sensitivity to classical mutations [45,89,91]. For the rest of the Ex20ins mutations, most of them do not respond to first- and third-generation TKIs [41], but are sensitive to second-generation TKIs [92]. Exceptionally, the three insertion mutations (D770_N771insG, D770>GY, and N771_P772insN) are at least partially responsive to first-generation EGFR TKIs [41].
Structural variations in Ex20ins mutations lead to the heterogeneity of TKI sensitivity. The insertions form a wedge that “pushes” the αC-helix and hold the αC in the active conformation [23,44], leading to constitutive activation of the receptor [23,44]. Sequence and conformational variation in the αC–β4 loop may function as a rheostat that regulates the kinase activity via modulating the αC-helix conformation [23]. Exceptionally, the insertion A763_764insFQEA that occurs within the αC-helix differs from insertions within the αC–β4 loop, and may constitutively activate the receptor most similarly to classical mutations, rather than other Ex20ins mutations. As might be expected, A763_764insFQEA is sensitive to first-, second- and third-generation EGFR TKIs [45,89,91], and is classified as a classical-like mutation. Other Ex20ins mutations are categorized as a unique class called Ex20-L mutations [27]. Ex20ins-L are sensitive only to select second-generation TKIs such as poziotinib [93], and Ex20ins-active TKIs such as CLN-081 [94] and mobocertinib [95]. Ex20ins-L mutations could be further subdivided into Ex20ins near αC-β4 loop (Ex20ins-NL) and far αC–β4 loop insertions (Ex20ins-FL). Ex20ins-NL is more sensitive to second-generation and Ex20ins-active TKIs than Ex20ins-FL (Figure 4).
Patients with single S768I mutation have variable responses to first-generation EGFR TKIs [90,96,97,98]. Patients whose cancers harbor theS768I mutation responded to afatinib [87], leading to FDA approval of this drug for this subset of patients. Notably, S768I usually co-occurs with additional EGFR mutations (7/8 cases in this study), making the response of the single S768I mutation to afatinib ambiguous. Co-occurrence of S768I with additional EGFR mutations might impact TKI sensitivity [99,100]. One patient with S768I+V769L, for example, was resistant to afatinib [101]. S768I-complex mutations are sensitive to the third-generation EGFR TKI osimertinib [102,103], though little data exists on single-mutant S768I sensitivity. S768I and its complex mutations are classified as PACC mutations. Ser768 is located at the αC–β4 loop. Substitution of Ser768 to isoline improves the hydrophobic interactions between the αC helix and the adjacent β9 strand, which might enthalpically stabilize the “αC-in” active conformation [21]. As such, S768I and its complex mutations are classified as PACC mutations (Figure 4).
Finally, little clinical or structural data exist for V774L and Q787L, though V774M and its complex mutations are classified as PACC mutations.

3.2.4. Exon 21 Mutations

Apart from L858R mutation, we found another exon 21 mutation L861X, including L861Q and L861R, in 2.3% of all EGFR mutations and 5.7% of rare EGFR mutations in the GENIE lung cancer dataset (Figure 2b). L861X mutations were also found to co-occur with additional EGFR mutations (Figure 2c). Preclinical and clinical studies show that L861Q mutation has an intermediate sensitivity to first-generation EGFR TKIs comparable to S768I and G719X mutations [42,43,104] (Figure 3). Patients with L861Q mutation are responsive to the second-generation EGFR TKI afatinib [87], which led to FDA approval of afatinib for this subtype [10]. In preclinical studies, L861Q mutations are sensitive to the third-generation EGFR TKI osimertinib [43], and a phase II trial reported patients with L861Q having partial responses to osimertinib [102]. Structurally, substitution of Leu861 to Gln allows the formation of new hydrogen bonds near the C-terminal of the αC helix that might enthalpically stabilize the “αC-in” active conformation [21]. L861X mutation and its complex mutations have been classified as PACC mutations (Figure 4).

3.2.5. EGFR Kinase Domain Duplication

In-frame, tandem duplication of EGFR exons 18–25, encoding EGFR kinase domain duplication (EGFR-KDD), has been identified in patients with NSCLC [105], with cases of a duplication of exons 14–26, 17–25 and 18–26 also reported in NSCLC [106]. EGFR-KDD occurs in 0.2–0.24% of all EGFR-mutant NSCLC patients [106,107,108]. Current evidence suggests that EGFR-KDD is sensitive to multiple EGFR TKIs [105,106]. Case studies show that NSCLC patients with EGFR-KDD can have durable partial response to either first-line [106] or second-line treatment with gefitinib [109], though at least one patient with EGFR-KDD did to respond to first-line gefitinib [106]. Case studies also show that NSCLC patients with EGFR-KDD are at least partially responsive to afatinib treatment [105,110], and the third-generation TKI osimertinib has been found to be effective in patients with EGFR-KDD [111,112].
Structure–function studies indicate that EGFR-KDD can form ligand-independent intramolecular asymmetric dimers in which one kinase domain functions as “activator” (donor) and the other functions as “receiver” (acceptor), and ligand-dependent intermolecular asymmetric dimers and higher-order oligomer. The linker between the two kinase domains provides additional enthalpic stabilization to promote activation. Preclinical studies show that the inhibition of EGFR-KDD activity can be achieved by the inhibition of intramolecular kinase activity (afatinib) and intermolecular kinase activity (cetuximab) [48]. Compared to gefitinib, structural studies predict osimertinib to bind more favorably with, and thus better inhibit, EGFR-KDD [113]. More structure–function studies are required to understand the detailed conformations when EGFR-KDD binds to the available TKIs, so that we can classify this type of mutations based on the structure-based grouping.

3.2.6. Uncommon Complex Mutations

We found uncommon complex mutations (rare + rare) occur in 36.5% of rare EGFR mutations and 6.7% of all EGFR mutations in the GENIE lung cancer dataset (Figure 2C). Of them, G719X complex mutations are the most common subtype of mutations and account for almost a half of all uncommon complex mutations (Figure 2C), with G719X + S768I most common one (Table 2). E709X complex mutations are the second most common of this subtype of mutations and account for 14.6% of all uncommon complex mutations (Figure 2C). Interestingly, all E709X mutations co-occur with G719X mutations (Table 2). We also found Ex20ins, L861X, L858X and S768I complex mutations (Figure 2C, Table 3).
Uncommon EGFR complex mutations encompass a wide range of patient responses to EGFR TKIs. Structure-based approaches classify the majority of uncommon EGFR complex mutations as PACC mutations, including E709X + G719X, G719X + rare and S768I + rare, like their single mutation partners. These complex mutations tend to yield more favorable patient outcomes in response to TKIs than the single rare mutations alone [88,104,114,115]. Interestingly, the sensitivity to EGFR TKIs is likely influenced by the specific co-occurring partner mutation. For example, patients with G719X + S768I mutations have dramatically different clinical outcomes compared to patients with G719X+L861Q mutations [104]. Single S768I mutation might not be sensitive to erlotinib, but co-occurrence with sensitizing EGFR mutations will confer sensitivity to the single S768I mutation [99].

4. Conclusions and Perspective

Structural studies on EGFR mutations have provided important information regarding EGFR biology and drug sensitivity. Comprehensive evaluation of structure alterations is very necessary for each mutations of EGFR kinase domain. Summary of these studies and the recent structure-based approaches have proposed a new classification of EGFR mutations. While many studies have emphasized the heterogeneity of a subset of mutations when grouped by exons, structure-based classification of EGFR mutations can better predict TKI sensitivity and patient outcomes than exon-based grouping. For example, one specific Ex20ins mutation, A763_764insFQEA, with similar activation mechanism to L858R and Ex19Del mutations, has been classified as a classical-like mutation, while the rest of the Ex20ins mutations have been classified as a unique group as Ex20ins-L mutations. This group of mutations have greater sensitivity to select second-generation EGFR TKIs than other groups.
Another advantage of the structure-based classification is identifying groups of mutations that, though occurring on different exons, confer similar sensitivity to EGFR TKIs. For example, G719X, L747P and S768I mutations, corresponding to exon 18, 19 and 20, respectively, were more sensitive to second-generation EGFR TKIs than first- and third-generation TKIs, and therefore were classified as PACC mutations. This kind of classification might provide important guidance for future oncology efforts, such as developing new TKIs, improving the design of clinical trials and matching patients with the best EGFR TKI.
Rare mutations, especially the complex mutations, need to be systematically evaluated by structure and function studies. Current studies mainly focus on common complex mutations. Nonetheless, preclinical and clinical data are limited. Preclinical studies are required to systematically analyze single rare mutations as well as the effects that complex partners add, both structurally and functionally. Rationally designed clinical studies, informed by structure–function research, will be required to generalize the relationship between mutations, TKI sensitivities, and patient outcomes.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/biom13020210/s1, Table S1: Ex19Del; Table S2: L858R; Table S3: E709X; Table S4: G719X; Table S5: Ex20ins; Table S6: S768I; Table S7: L861X; Table S8: uncommon mutations; Table S9: complex mutations.

Author Contributions

Conceptualization, Z.D.; writing—original draft preparation, Z.D.; methodology, Z.D. and Y.Z.; formal analysis, Y.Z. and Z.D.; resources, Z.D. and Y.Z.; writing—review and editing, Z.D., J.S., Y.Z., N.H., Q.X., H.C., N.F. and X.X.; supervision, Z.D. All authors have read and agreed to the published version of the manuscript.

Funding

Z.D. is supported by the 2018 AACR-AstraZeneca Lung Cancer Research Fellowship, (Grant No. 18-40-12-DU), and the Fundamental Research Funds for the Central Universities (2242022R10072). Q.X. and N.H. are supported by the Summer Research Trainee Program (202341053).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The authors declare that all data supporting the findings of this study are provided in the Supplementary Data file. The GENIE Cohort v12.0-public dataset is publicly available through Sage Bionetworks (https://www.aacr.org/professionals/research/aacr-project-genie/aacr-project-genie-data/, accessed on 10 January 2023).

Acknowledgments

We thank David Westover for his valuable suggestions and English proofreading on this manuscript. We thank Minrui Fan and Yong Liu for the valuable discussion on this manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
  2. Lusk, C.M.; Watza, D.; Dyson, G.; Craig, D.; Ratliff, V.; Wenzlaff, A.S.; Lonardo, F.; Bollig-Fischer, A.; Bepler, G.; Purrington, K.; et al. Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non-Small Cell Lung Cancer Patients. Clin. Cancer Res. 2019, 25, 4300–4308. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Gillette, M.A.; Satpathy, S.; Cao, S.; Dhanasekaran, S.M.; Vasaikar, S.V.; Krug, K.; Petralia, F.; Li, Y.; Liang, W.W.; Reva, B.; et al. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell 2020, 182, 200–225.e35. [Google Scholar] [CrossRef] [PubMed]
  4. Chen, J.; Yang, H.; Teo, A.S.M.; Amer, L.B.; Sherbaf, F.G.; Tan, C.Q.; Alvarez, J.J.S.; Lu, B.; Lim, J.Q.; Takano, A.; et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat. Genet. 2020, 52, 177–186. [Google Scholar] [CrossRef]
  5. Boeckx, B.; Shahi, R.B.; Smeets, D.; De Brakeleer, S.; Decoster, L.; Van Brussel, T.; Galdermans, D.; Vercauter, P.; Decoster, L.; Alexander, P.; et al. The genomic landscape of nonsmall cell lung carcinoma in never smokers. Int. J. Cancer 2020, 146, 3207–3218. [Google Scholar] [CrossRef]
  6. Shigematsu, H.; Lin, L.; Takahashi, T.; Nomura, M.; Suzuki, M.; Wistuba, I.I.; Fong, K.M.; Lee, H.; Toyooka, S.; Shimizu, N.; et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005, 97, 339–346. [Google Scholar] [CrossRef] [Green Version]
  7. Zhang, T.; Joubert, P.; Ansari-Pour, N.; Zhao, W.; Hoang, P.H.; Lokanga, R.; Moye, A.L.; Rosenbaum, J.; Gonzalez-Perez, A.; Martinez-Jimenez, F.; et al. Genomic and evolutionary classification of lung cancer in never smokers. Nat. Genet. 2021, 53, 1348–1359. [Google Scholar] [CrossRef]
  8. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129–2139. [Google Scholar] [CrossRef]
  9. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497–1500. [Google Scholar] [CrossRef] [Green Version]
  10. Mok, T.S.; Wu, Y.L.; Thongprasert, S.; Yang, C.H.; Chu, D.T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361, 947–957. [Google Scholar] [CrossRef]
  11. Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Palmero, R.; Garcia-Gomez, R.; Pallares, C.; Sanchez, J.M.; et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13, 239–246. [Google Scholar] [CrossRef] [PubMed]
  12. Ferguson, K.M.; Berger, M.B.; Mendrola, J.M.; Cho, H.S.; Leahy, D.J.; Lemmon, M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 2003, 11, 507–517. [Google Scholar] [CrossRef] [PubMed]
  13. Arkhipov, A.; Shan, Y.; Das, R.; Endres, N.F.; Eastwood, M.P.; Wemmer, D.E.; Kuriyan, J.; Shaw, D.E. Architecture and membrane interactions of the EGF receptor. Cell 2013, 152, 557–569. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Srinivasan, S.; Regmi, R.; Lin, X.; Dreyer, C.A.; Chen, X.; Quinn, S.D.; He, W.; Coleman, M.A.; Carraway, K.L., 3rd; Zhang, B.; et al. Ligand-induced transmembrane conformational coupling in monomeric EGFR. Nat. Commun. 2022, 13, 3709. [Google Scholar] [CrossRef] [PubMed]
  15. Zanetti-Domingues, L.C.; Korovesis, D.; Needham, S.R.; Tynan, C.J.; Sagawa, S.; Roberts, S.K.; Kuzmanic, A.; Ortiz-Zapater, E.; Jain, P.; Roovers, R.C.; et al. The architecture of EGFR’s basal complexes reveals autoinhibition mechanisms in dimers and oligomers. Nat. Commun. 2018, 9, 4325. [Google Scholar] [CrossRef] [Green Version]
  16. Zhang, X.; Gureasko, J.; Shen, K.; Cole, P.A.; Kuriyan, J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125, 1137–1149. [Google Scholar] [CrossRef] [Green Version]
  17. Huang, Y.; Bharill, S.; Karandur, D.; Peterson, S.M.; Marita, M.; Shi, X.; Kaliszewski, M.J.; Smith, A.W.; Isacoff, E.Y.; Kuriyan, J. Molecular basis for multimerization in the activation of the epidermal growth factor receptor. Elife 2016, 5, e14107. [Google Scholar] [CrossRef]
  18. Needham, S.R.; Roberts, S.K.; Arkhipov, A.; Mysore, V.P.; Tynan, C.J.; Zanetti-Domingues, L.C.; Kim, E.T.; Losasso, V.; Korovesis, D.; Hirsch, M.; et al. EGFR oligomerization organizes kinase-active dimers into competent signalling platforms. Nat. Commun. 2016, 7, 13307. [Google Scholar] [CrossRef] [Green Version]
  19. Huang, Y.; Ognjenovic, J.; Karandur, D.; Miller, K.; Merk, A.; Subramaniam, S.; Kuriyan, J. A molecular mechanism for the generation of ligand-dependent differential outputs by the epidermal growth factor receptor. Elife 2021, 10, e73218. [Google Scholar] [CrossRef]
  20. Yun, C.H.; Boggon, T.J.; Li, Y.; Woo, M.S.; Greulich, H.; Meyerson, M.; Eck, M.J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007, 11, 217–227. [Google Scholar] [CrossRef]
  21. Shan, Y.; Eastwood, M.P.; Zhang, X.; Kim, E.T.; Arkhipov, A.; Dror, R.O.; Jumper, J.; Kuriyan, J.; Shaw, D.E. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 2012, 149, 860–870. [Google Scholar] [CrossRef] [Green Version]
  22. Foster, S.A.; Whalen, D.M.; Ozen, A.; Wongchenko, M.J.; Yin, J.; Yen, I.; Schaefer, G.; Mayfield, J.D.; Chmielecki, J.; Stephens, P.J.; et al. Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. Cancer Cell 2016, 29, 477–493. [Google Scholar] [CrossRef] [Green Version]
  23. Ruan, Z.; Kannan, N. Altered conformational landscape and dimerization dependency underpins the activation of EGFR by alphaC-beta4 loop insertion mutations. Proc. Natl. Acad. Sci. USA 2018, 115, E8162–E8171. [Google Scholar] [CrossRef] [Green Version]
  24. Red Brewer, M.; Yun, C.H.; Lai, D.; Lemmon, M.A.; Eck, M.J.; Pao, W. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proc. Natl. Acad. Sci. USA 2013, 110, E3595–E3604. [Google Scholar] [CrossRef] [Green Version]
  25. Yan, X.E.; Ayaz, P.; Zhu, S.J.; Zhao, P.; Liang, L.; Zhang, C.H.; Wu, Y.C.; Li, J.L.; Choi, H.G.; Huang, X.; et al. Structural Basis of AZD9291 Selectivity for EGFR T790M. J. Med. Chem. 2020, 63, 8502–8511. [Google Scholar] [CrossRef]
  26. Sharma, S.V.; Bell, D.W.; Settleman, J.; Haber, D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7, 169–181. [Google Scholar] [CrossRef]
  27. Robichaux, J.P.; Le, X.; Vijayan, R.S.K.; Hicks, J.K.; Heeke, S.; Elamin, Y.Y.; Lin, H.Y.; Udagawa, H.; Skoulidis, F.; Tran, H.; et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 2021, 597, 732–737. [Google Scholar] [CrossRef]
  28. Yang, J.C.; Wu, Y.L.; Schuler, M.; Sebastian, M.; Popat, S.; Yamamoto, N.; Zhou, C.; Hu, C.P.; O’Byrne, K.; Feng, J.; et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015, 16, 141–151. [Google Scholar] [CrossRef] [Green Version]
  29. Xu, H.; Yang, G.; Li, W.; Li, J.; Hao, X.; Xing, P.; Yang, Y.; Wang, Y. EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes. Front. Oncol. 2021, 11, 713483. [Google Scholar] [CrossRef]
  30. Moran, T.; Taus, A.; Arriola, E.; Aguado, C.; Domine, M.; Rueda, A.G.; Calles, A.; Cedres, S.; Vinolas, N.; Isla, D.; et al. Clinical Activity of Afatinib in Patients with Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study. Clin. Lung Cancer 2020, 21, 428–436.e2. [Google Scholar] [CrossRef]
  31. She, Y.; Li, S.; Deng, J.; Ren, Y.; Zhao, M.; Zhong, Y.; He, Y.; Chen, Q.; Zhao, D.; Zhu, Y.; et al. Clinicopathologic characteristics and prognostic impact of atypical EGFR mutations in completely resected lung adenocarcinoma. Eur. J. Cancer 2022, 177, 53–62. [Google Scholar] [CrossRef] [PubMed]
  32. Sehgal, K.; Rangachari, D.; VanderLaan, P.A.; Kobayashi, S.S.; Costa, D.B. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. Oncologist 2021, 26, 281–287. [Google Scholar] [CrossRef] [PubMed]
  33. Kanazu, M.; Mori, M.; Kimura, M.; Nishino, K.; Shiroyama, T.; Nagatomo, I.; Ihara, S.; Komuta, K.; Suzuki, H.; Hirashima, T.; et al. Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study. Thorac. Cancer 2021, 12, 90–96. [Google Scholar] [CrossRef] [PubMed]
  34. Gerber, D.E.; Mayer, M.; Gagan, J.; von Itzstein, M.S. Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report. JTO Clin. Res. Rep. 2022, 3, 100291. [Google Scholar] [CrossRef]
  35. Zhou, T.; Zhou, X.; Li, P.; Qi, C.; Ling, Y. EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: A case report. J. Thorac. Dis. 2018, 10, E802–E805. [Google Scholar] [CrossRef]
  36. Huang, X.; Yang, Y.; Wang, P.; Wang, J.; Chen, S.; Mao, X.; Ding, L. A rare EGFR mutation L747P conferred therapeutic efficacy to both ge fi tinib and osimertinib: A case report. Lung Cancer 2020, 150, 9–11. [Google Scholar] [CrossRef]
  37. Meador, C.B.; Sequist, L.V.; Piotrowska, Z. Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates. Cancer Discov. 2021, 11, 2145–2157. [Google Scholar] [CrossRef]
  38. Yang, G.; Li, J.; Xu, H.; Yang, Y.; Yang, L.; Xu, F.; Xia, B.; Zhu, V.W.; Nagasaka, M.; Yang, Y.; et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer 2020, 145, 186–194. [Google Scholar] [CrossRef]
  39. Yasuda, H.; Ichihara, E.; Sakakibara-Konishi, J.; Zenke, Y.; Takeuchi, S.; Morise, M.; Hotta, K.; Sato, M.; Matsumoto, S.; Tanimoto, A.; et al. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Lung Cancer 2021, 162, 140–146. [Google Scholar] [CrossRef]
  40. Bazhenova, L.; Minchom, A.; Viteri, S.; Bauml, J.M.; Ou, S.I.; Gadgeel, S.M.; Trigo, J.M.; Backenroth, D.; Li, T.; Londhe, A.; et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer 2021, 162, 154–161. [Google Scholar] [CrossRef]
  41. Qin, Y.; Jian, H.; Tong, X.; Wu, X.; Wang, F.; Shao, Y.W.; Zhao, X. Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors. Mol. Oncol. 2020, 14, 1695–1704. [Google Scholar] [CrossRef]
  42. Kobayashi, Y.; Mitsudomi, T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci. 2016, 107, 1179–1186. [Google Scholar] [CrossRef]
  43. Banno, E.; Togashi, Y.; Nakamura, Y.; Chiba, M.; Kobayashi, Y.; Hayashi, H.; Terashima, M.; de Velasco, M.A.; Sakai, K.; Fujita, Y.; et al. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor? Cancer Sci. 2016, 107, 1134–1140. [Google Scholar] [CrossRef] [Green Version]
  44. Yasuda, H.; Park, E.; Yun, C.H.; Sng, N.J.; Lucena-Araujo, A.R.; Yeo, W.L.; Huberman, M.S.; Cohen, D.W.; Nakayama, S.; Ishioka, K.; et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci. Transl. Med. 2013, 5, 216ra177. [Google Scholar] [CrossRef] [Green Version]
  45. Vasconcelos, P.; Gergis, C.; Viray, H.; Varkaris, A.; Fujii, M.; Rangachari, D.; VanderLaan, P.A.; Kobayashi, I.S.; Kobayashi, S.S.; Costa, D.B. EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors. JTO Clin. Res. Rep. 2020, 1, 100051. [Google Scholar] [CrossRef]
  46. Brown, B.P.; Zhang, Y.K.; Westover, D.; Yan, Y.; Qiao, H.; Huang, V.; Du, Z.; Smith, J.A.; Ross, J.S.; Miller, V.A.; et al. On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. Clin. Cancer Res. 2019, 25, 3341–3351. [Google Scholar] [CrossRef] [Green Version]
  47. Ikemura, S.; Yasuda, H.; Matsumoto, S.; Kamada, M.; Hamamoto, J.; Masuzawa, K.; Kobayashi, K.; Manabe, T.; Arai, D.; Nakachi, I.; et al. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proc. Natl. Acad. Sci. USA 2019, 116, 10025–10030. [Google Scholar] [CrossRef] [Green Version]
  48. Du, Z.; Brown, B.P.; Kim, S.; Ferguson, D.; Pavlick, D.C.; Jayakumaran, G.; Benayed, R.; Gallant, J.N.; Zhang, Y.K.; Yan, Y.; et al. Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting. Nat. Commun. 2021, 12, 1382. [Google Scholar] [CrossRef]
  49. Shan, Y.; Arkhipov, A.; Kim, E.T.; Pan, A.C.; Shaw, D.E. Transitions to catalytically inactive conformations in EGFR kinase. Proc. Natl. Acad. Sci. USA 2013, 110, 7270–7275. [Google Scholar] [CrossRef] [Green Version]
  50. Wu, Y.L.; Cheng, Y.; Zhou, X.; Lee, K.H.; Nakagawa, K.; Niho, S.; Tsuji, F.; Linke, R.; Rosell, R.; Corral, J.; et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial. Lancet Oncol. 2017, 18, 1454–1466. [Google Scholar] [CrossRef]
  51. Passaro, A.; Janne, P.A.; Mok, T.; Peters, S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat. Cancer 2021, 2, 377–391. [Google Scholar] [CrossRef] [PubMed]
  52. Soria, J.C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K.H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 378, 113–125. [Google Scholar] [CrossRef]
  53. Cho, B.C.; Chewaskulyong, B.; Lee, K.H.; Dechaphunkul, A.; Sriuranpong, V.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; et al. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. J. Thorac. Oncol. 2019, 14, 99–106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Ramalingam, S.S.; Vansteenkiste, J.; Planchard, D.; Cho, B.C.; Gray, J.E.; Ohe, Y.; Zhou, C.; Reungwetwattana, T.; Cheng, Y.; Chewaskulyong, B.; et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N. Engl. J. Med. 2020, 382, 41–50. [Google Scholar] [CrossRef] [PubMed]
  55. Lu, S.; Wang, Q.; Zhang, G.; Dong, X.; Yang, C.T.; Song, Y.; Chang, G.C.; Lu, Y.; Pan, H.; Chiu, C.H.; et al. Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results from the APOLLO Registrational Trial. J. Thorac. Oncol. 2022, 17, 411–422. [Google Scholar] [CrossRef]
  56. Shi, Y.; Zhang, S.; Hu, X.; Feng, J.; Ma, Z.; Zhou, J.; Yang, N.; Wu, L.; Liao, W.; Zhong, D.; et al. Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients with Advanced NSCLC With EGFR T790M Mutation. J. Thorac. Oncol. 2020, 15, 1015–1026. [Google Scholar] [CrossRef] [Green Version]
  57. Nagasaka, M.; Zhu, V.W.; Lim, S.M.; Greco, M.; Wu, F.; Ou, S.I. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors for Advanced EGFR+ NSCLC. J. Thorac. Oncol. 2021, 16, 740–763. [Google Scholar] [CrossRef]
  58. Eno, M.S.; Brubaker, J.D.; Campbell, J.E.; De Savi, C.; Guzi, T.J.; Williams, B.D.; Wilson, D.; Wilson, K.; Brooijmans, N.; Kim, J.; et al. Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. J. Med. Chem. 2022, 65, 9662–9677. [Google Scholar] [CrossRef]
  59. To, C.; Beyett, T.S.; Jang, J.; Feng, W.W.; Bahcall, M.; Haikala, H.M.; Shin, B.H.; Heppner, D.E.; Rana, J.K.; Leeper, B.A.; et al. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nat. Cancer 2022, 3, 402–417. [Google Scholar] [CrossRef]
  60. Pugh, T.J.; Bell, J.L.; Bruce, J.P.; Doherty, G.J.; Galvin, M.; Green, M.F.; Hunter-Zinck, H.; Kumari, P.; Lenoue-Newton, M.L.; Li, M.M.; et al. AACR Project GENIE: 100,000 Cases and Beyond. Cancer Discov. 2022, 12, 2044–2057. [Google Scholar] [CrossRef]
  61. Zhou, W.; Ercan, D.; Chen, L.; Yun, C.H.; Li, D.; Capelletti, M.; Cortot, A.B.; Chirieac, L.; Iacob, R.E.; Padera, R.; et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462, 1070–1074. [Google Scholar] [CrossRef] [Green Version]
  62. Schuler, M.; Yang, J.C.; Park, K.; Kim, J.H.; Bennouna, J.; Chen, Y.M.; Chouaid, C.; De Marinis, F.; Feng, J.F.; Grossi, F.; et al. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial. Ann. Oncol. 2016, 27, 417–423. [Google Scholar] [CrossRef]
  63. He, M.; Capelletti, M.; Nafa, K.; Yun, C.H.; Arcila, M.E.; Miller, V.A.; Ginsberg, M.S.; Zhao, B.; Kris, M.G.; Eck, M.J.; et al. EGFR exon 19 insertions: A new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin. Cancer Res. 2012, 18, 1790–1797. [Google Scholar] [CrossRef] [Green Version]
  64. Baek, J.H.; Sun, J.M.; Min, Y.J.; Cho, E.K.; Cho, B.C.; Kim, J.H.; Ahn, M.J.; Park, K. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea. Lung Cancer 2015, 87, 148–154. [Google Scholar] [CrossRef]
  65. Kohsaka, S.; Nagano, M.; Ueno, T.; Suehara, Y.; Hayashi, T.; Shimada, N.; Takahashi, K.; Suzuki, K.; Takamochi, K.; Takahashi, F.; et al. A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. Sci. Transl. Med. 2017, 9, eaan6566. [Google Scholar] [CrossRef] [Green Version]
  66. Xu, J.; Jin, B.; Chu, T.; Dong, X.; Yang, H.; Zhang, Y.; Wu, D.; Lou, Y.; Zhang, X.; Wang, H.; et al. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. Lung Cancer 2016, 96, 87–92. [Google Scholar] [CrossRef] [PubMed]
  67. Tamirat, M.Z.; Koivu, M.; Elenius, K.; Johnson, M.S. Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation. PLoS ONE 2019, 14, e0222814. [Google Scholar] [CrossRef]
  68. Brown, B.P.; Zhang, Y.K.; Kim, S.; Finneran, P.; Yan, Y.; Du, Z.; Kim, J.; Hartzler, A.L.; LeNoue-Newton, M.L.; Smith, A.W.; et al. Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer. Proc. Natl. Acad. Sci. USA 2022, 119, e2206588119. [Google Scholar] [CrossRef]
  69. Truini, A.; Starrett, J.H.; Stewart, T.; Ashtekar, K.; Walther, Z.; Wurtz, A.; Lu, D.; Park, J.H.; DeVeaux, M.; Song, X.; et al. The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Clin. Cancer Res. 2019, 25, 6382–6391. [Google Scholar] [CrossRef]
  70. Zhao, C.; Jiang, T.; Li, J.; Wang, Y.; Su, C.; Chen, X.; Ren, S.; Li, X.; Zhou, C. The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer. Transl. Lung Cancer Res. 2020, 9, 1149–1158. [Google Scholar] [CrossRef]
  71. Yun, C.H.; Mengwasser, K.E.; Toms, A.V.; Woo, M.S.; Greulich, H.; Wong, K.K.; Meyerson, M.; Eck, M.J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. USA 2008, 105, 2070–2075. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Yu, H.A.; Pao, W. Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer. Nat. Rev. Clin. Oncol. 2013, 10, 551–552. [Google Scholar] [CrossRef] [PubMed]
  73. Bar, J.; Peled, N.; Schokrpur, S.; Wolner, M.; Rotem, O.; Girard, N.; Aboubakar Nana, F.; Derijcke, S.; Kian, W.; Patel, S.; et al. UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN). J. Thorac. Oncol. 2022; in press. [Google Scholar] [CrossRef]
  74. Kobayashi, Y.; Togashi, Y.; Yatabe, Y.; Mizuuchi, H.; Jangchul, P.; Kondo, C.; Shimoji, M.; Sato, K.; Suda, K.; Tomizawa, K.; et al. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clin. Cancer Res. 2015, 21, 5305–5313. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Minari, R.; Leonetti, A.; Gnetti, L.; Zielli, T.; Ventura, L.; Bottarelli, L.; Lagrasta, C.; La Monica, S.; Petronini, P.G.; Alfieri, R.; et al. Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib. Anticancer Drugs 2021, 32, 758–762. [Google Scholar] [CrossRef]
  76. Li, Y.; Lin, Y.; Wu, J.; Ye, F. Meningeal metastasis patients with EGFR G724S who develop resistance to osimertinib benefit from the addition of afatinib. Transl. Lung Cancer Res. 2020, 9, 2188–2190. [Google Scholar] [CrossRef]
  77. Fang, W.; Huang, Y.; Gan, J.; Zheng, Q.; Zhang, L. Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy. J. Thorac. Oncol. 2020, 15, e36–e37. [Google Scholar] [CrossRef]
  78. Wei, Y.; Jiang, B.; Liu, S.; Zhang, Z.; Fang, W.; Yang, Y.; Li, X.; Zhao, J.; Zhao, H. Afatinib as a Potential Therapeutic Option for Patients with NSCLC With EGFR G724S. JTO Clin. Res. Rep. 2021, 2, 100193. [Google Scholar] [CrossRef]
  79. Wang, Y.T.; Ning, W.W.; Li, J.; Huang, J.A. Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: A case report. J. Thorac. Dis. 2016, 8, E542–E546. [Google Scholar] [CrossRef] [Green Version]
  80. Huang, J.; Wang, Y.; Zhai, Y.; Wang, J. Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report. Thorac. Cancer 2018, 9, 745–749. [Google Scholar] [CrossRef]
  81. Li, J.; Zhu, L.; Stebbing, J.; Peng, L. Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation. J. Cancer Res. Ther. 2022, 18, 1436–1439. [Google Scholar] [CrossRef]
  82. Li, Y.; Guo, W.; Jiang, B.; Han, C.; Ye, F.; Wu, J. Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases. Front. Oncol. 2022, 12, 863771. [Google Scholar] [CrossRef]
  83. Yoshizawa, T.; Uchibori, K.; Araki, M.; Matsumoto, S.; Ma, B.; Kanada, R.; Seto, Y.; Oh-Hara, T.; Koike, S.; Ariyasu, R.; et al. Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity. NPJ Precis. Oncol. 2021, 5, 32. [Google Scholar] [CrossRef]
  84. Friedlaender, A.; Subbiah, V.; Russo, A.; Banna, G.L.; Malapelle, U.; Rolfo, C.; Addeo, A. EGFR and HER2 exon 20 insertions in solid tumours: From biology to treatment. Nat. Rev. Clin. Oncol. 2022, 19, 51–69. [Google Scholar] [CrossRef]
  85. Lin, Y.T.; Shih, J.Y. Not All EGFR Exon 20 Insertions Are Created Equal. JTO Clin. Res. Rep. 2020, 1, 100069. [Google Scholar] [CrossRef]
  86. Shi, C.; Xing, R.; Li, M.; Feng, J.; Sun, R.; Wei, B.; Guo, Y.; Ma, J.; Wang, H. Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations. Front. Oncol. 2022, 12, 949304. [Google Scholar] [CrossRef]
  87. Yang, J.C.; Sequist, L.V.; Geater, S.L.; Tsai, C.M.; Mok, T.S.; Schuler, M.; Yamamoto, N.; Yu, C.J.; Ou, S.H.; Zhou, C.; et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015, 16, 830–838. [Google Scholar] [CrossRef]
  88. Beau-Faller, M.; Prim, N.; Ruppert, A.M.; Nanni-Metellus, I.; Lacave, R.; Lacroix, L.; Escande, F.; Lizard, S.; Pretet, J.L.; Rouquette, I.; et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: A multicentre observational study by the French ERMETIC-IFCT network. Ann. Oncol. 2014, 25, 126–131. [Google Scholar] [CrossRef]
  89. Naidoo, J.; Sima, C.S.; Rodriguez, K.; Busby, N.; Nafa, K.; Ladanyi, M.; Riely, G.J.; Kris, M.G.; Arcila, M.E.; Yu, H.A. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. Cancer 2015, 121, 3212–3220. [Google Scholar] [CrossRef] [Green Version]
  90. Janning, M.; Suptitz, J.; Albers-Leischner, C.; Delpy, P.; Tufman, A.; Velthaus-Rusik, J.L.; Reck, M.; Jung, A.; Kauffmann-Guerrero, D.; Bonzheim, I.; et al. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). Ann. Oncol. 2022, 33, 602–615. [Google Scholar] [CrossRef]
  91. Voon, P.J.; Tsui, D.W.; Rosenfeld, N.; Chin, T.M. EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib--Letter. Mol. Cancer Ther. 2013, 12, 2614–2615. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  92. Kobayashi, I.S.; Viray, H.; Rangachari, D.; Kobayashi, S.S.; Costa, D.B. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. Cells 2021, 10, 3561. [Google Scholar] [CrossRef] [PubMed]
  93. Elamin, Y.Y.; Robichaux, J.P.; Carter, B.W.; Altan, M.; Tran, H.; Gibbons, D.L.; Heeke, S.; Fossella, F.V.; Lam, V.K.; Le, X.; et al. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell 2022, 40, 754–767.e6. [Google Scholar] [CrossRef] [PubMed]
  94. Udagawa, H.; Hasako, S.; Ohashi, A.; Fujioka, R.; Hakozaki, Y.; Shibuya, M.; Abe, N.; Komori, T.; Haruma, T.; Terasaka, M.; et al. TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. Mol. Cancer Res. 2019, 17, 2233–2243. [Google Scholar] [CrossRef] [Green Version]
  95. Gonzalvez, F.; Vincent, S.; Baker, T.E.; Gould, A.E.; Li, S.; Wardwell, S.D.; Nadworny, S.; Ning, Y.; Zhang, S.; Huang, W.S.; et al. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. Cancer Discov. 2021, 11, 1672–1687. [Google Scholar] [CrossRef]
  96. Leal, J.L.; Alexander, M.; Itchins, M.; Wright, G.M.; Kao, S.; Hughes, B.G.M.; Pavlakis, N.; Clarke, S.; Gill, A.J.; Ainsworth, H.; et al. EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer. Clin. Lung Cancer 2021, 22, e859–e869. [Google Scholar] [CrossRef]
  97. Popat, S.; Hsia, T.C.; Hung, J.Y.; Jung, H.A.; Shih, J.Y.; Park, C.K.; Lee, S.H.; Okamoto, T.; Ahn, H.K.; Lee, Y.C.; et al. Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG). Oncologist 2022, 27, 255–265. [Google Scholar] [CrossRef]
  98. Hellmann, M.D.; Reva, B.; Yu, H.; Rusch, V.W.; Rizvi, N.A.; Kris, M.G.; Arcila, M.E. Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib. J. Thorac. Oncol. 2014, 9, e73–e74. [Google Scholar] [CrossRef] [Green Version]
  99. Leventakos, K.; Kipp, B.R.; Rumilla, K.M.; Winters, J.L.; Yi, E.S.; Mansfield, A.S. S768I Mutation in EGFR in Patients with Lung Cancer. J. Thorac. Oncol. 2016, 11, 1798–1801. [Google Scholar] [CrossRef] [Green Version]
  100. Kuiper, J.L.; Hashemi, S.M.; Thunnissen, E.; Snijders, P.J.; Grunberg, K.; Bloemena, E.; Sie, D.; Postmus, P.E.; Heideman, D.A.; Smit, E.F. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Br. J. Cancer 2016, 115, 1504–1512. [Google Scholar] [CrossRef]
  101. Niogret, J.; Coudert, B.; Boidot, R. Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L. J. Thorac. Oncol. 2018, 13, e113. [Google Scholar] [CrossRef] [Green Version]
  102. Cho, J.H.; Lim, S.H.; An, H.J.; Kim, K.H.; Park, K.U.; Kang, E.J.; Choi, Y.H.; Ahn, M.S.; Lee, M.H.; Sun, J.M.; et al. Osimertinib for Patients with Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). J. Clin. Oncol. 2020, 38, 488–495. [Google Scholar] [CrossRef]
  103. Eide, I.J.Z.; Stensgaard, S.; Helland, A.; Ekman, S.; Mellemgaard, A.; Hansen, K.H.; Cicenas, S.; Koivunen, J.; Gronberg, B.H.; Sorensen, B.S.; et al. Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: A post-hoc subgroup analysis with pooled data from two phase II clinical trials. Transl. Lung Cancer Res. 2022, 11, 953–963. [Google Scholar] [CrossRef]
  104. Chiu, C.H.; Yang, C.T.; Shih, J.Y.; Huang, M.S.; Su, W.C.; Lai, R.S.; Wang, C.C.; Hsiao, S.H.; Lin, Y.C.; Ho, C.L.; et al. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. J. Thorac. Oncol. 2015, 10, 793–799. [Google Scholar] [CrossRef] [Green Version]
  105. Gallant, J.N.; Sheehan, J.H.; Shaver, T.M.; Bailey, M.; Lipson, D.; Chandramohan, R.; Red Brewer, M.; York, S.J.; Kris, M.G.; Pietenpol, J.A.; et al. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Cancer Discov. 2015, 5, 1155–1163. [Google Scholar] [CrossRef] [Green Version]
  106. Wang, J.; Li, X.; Xue, X.; Ou, Q.; Wu, X.; Liang, Y.; Wang, X.; You, M.; Shao, Y.W.; Zhang, Z.; et al. Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC. Int. J. Cancer 2019, 144, 2677–2682. [Google Scholar] [CrossRef] [Green Version]
  107. Costa, D.B. Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: Moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements. Transl. Lung Cancer Res. 2016, 5, 331–337. [Google Scholar] [CrossRef] [Green Version]
  108. Wu, D.; Xie, Y.; Jin, C.; Qiu, J.; Hou, T.; Du, H.; Chen, S.; Xiang, J.; Shi, X.; Liu, J. The landscape of kinase domain duplication in Chinese lung cancer patients. Ann. Transl. Med. 2020, 8, 1642. [Google Scholar] [CrossRef]
  109. Baik, C.S.; Wu, D.; Smith, C.; Martins, R.G.; Pritchard, C.C. Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication. J. Thorac. Oncol. 2015, 10, e97-99. [Google Scholar] [CrossRef] [Green Version]
  110. Chen, D.; Li, X.L.; Wu, B.; Zheng, X.B.; Wang, W.X.; Chen, H.F.; Dong, Y.Y.; Xu, C.W.; Fang, M.Y. A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib. Front. Oncol. 2020, 10, 867. [Google Scholar] [CrossRef]
  111. Zhang, L.D.; Gao, H.; Qin, S.M.; Zeng, Q.; Chen, Q.F. Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18-25 kinase domain duplication: Report of two cases. Anticancer Drugs 2022, 33, e486–e490. [Google Scholar] [CrossRef] [PubMed]
  112. Taek Kim, J.; Zhang, W.; Lopategui, J.; Vail, E.; Balmanoukian, A. Patient with Stage IV NSCLC and CNS Metastasis with EGFR Exon 18-25 Kinase Domain Duplication with Response to Osimertinib as a First-Line Therapy. JCO Precis. Oncol. 2021, 5, 88–92. [Google Scholar] [CrossRef] [PubMed]
  113. Jin, R.; Li, J.; Jin, Z.; Lu, Y.; Shao, Y.W.; Li, W.; Zhao, G.; Xia, Y. Osimertinib confers potent binding affinity to EGFR kinase domain duplication. Int. J. Cancer 2019, 145, 2884–2885. [Google Scholar] [CrossRef]
  114. Wu, J.Y.; Shih, J.Y. Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer. OncoTargets Ther. 2016, 9, 6137–6145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  115. Cheng, C.; Wang, R.; Li, Y.; Pan, Y.; Zhang, Y.; Li, H.; Zheng, D.; Zheng, S.; Shen, X.; Sun, Y.; et al. EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis. Sci. Rep. 2015, 5, 13959. [Google Scholar] [CrossRef]
Biomolecules 13 00210 g001 550
Figure 1. Schematic representation showing the structure of the EGFR kinase domain. (a) Src-like inactive conformation (PDB ID: 2GS7) and (b) active conformation (PDB ID: 2ITP) with important residues and structural features labelled.
Figure 1. Schematic representation showing the structure of the EGFR kinase domain. (a) Src-like inactive conformation (PDB ID: 2GS7) and (b) active conformation (PDB ID: 2ITP) with important residues and structural features labelled.
Biomolecules 13 00210 g001
Biomolecules 13 00210 g002 550
Figure 2. The frequencies of EGFR mutations in NSCLC. (a) Data were acquired from GENIE dataset (GENIE Cohort v12.0-public, n = 153,834). Data were filtered to contain mutations from NSCLC (n = 22,050). The common resistance mutations T790M and C797S were filtered out. (b) Pie chart showing the frequency of different uncommon EGFR mutations in NSCLC. (c) Pie chart showing the frequency of different uncommon complex EGFR mutations in NSCLC.
Figure 2. The frequencies of EGFR mutations in NSCLC. (a) Data were acquired from GENIE dataset (GENIE Cohort v12.0-public, n = 153,834). Data were filtered to contain mutations from NSCLC (n = 22,050). The common resistance mutations T790M and C797S were filtered out. (b) Pie chart showing the frequency of different uncommon EGFR mutations in NSCLC. (c) Pie chart showing the frequency of different uncommon complex EGFR mutations in NSCLC.
Biomolecules 13 00210 g002
Biomolecules 13 00210 g003 550
Figure 3. The position of EGFR mutations and sensitivity to EGFR TKIs based on exon-grouped classification. (a) Exons 18–21 in the tyrosine kinase region where the relevant mutations are located are expanded, and a detailed list of EGFR mutations in these exons is shown in the boxes below. TM, transmembrane; JM, juxtamembrane; KD, kinase domain. (b) The sensitivity to EGFR TKIs based on exon-grouped classification. Gray, insensitive to EGFR TKIs. Green, sensitive to EGFR TKIs in which the light-to-strong color represents weak-to-strong sensitivity.
Figure 3. The position of EGFR mutations and sensitivity to EGFR TKIs based on exon-grouped classification. (a) Exons 18–21 in the tyrosine kinase region where the relevant mutations are located are expanded, and a detailed list of EGFR mutations in these exons is shown in the boxes below. TM, transmembrane; JM, juxtamembrane; KD, kinase domain. (b) The sensitivity to EGFR TKIs based on exon-grouped classification. Gray, insensitive to EGFR TKIs. Green, sensitive to EGFR TKIs in which the light-to-strong color represents weak-to-strong sensitivity.
Biomolecules 13 00210 g003
Biomolecules 13 00210 g004 550
Figure 4. The positions and structure-based classification of EGFR mutations. (a) A detailed list of EGFR mutations in each exon are shown in the below boxes. Different colors of each box represent different classes of mutations following structure-based classification. Ex20ins-L, exon 20 loop insertions; Ex20ins-NL, exon 20 near-loop insertions; Ex20ins-FL, exon 20 far-loop insertions; PACC, P-loop and αC-helix compressing mutations. (b) The sensitivity to EGFR TKIs of each group of mutations based on structure-based classification.
Figure 4. The positions and structure-based classification of EGFR mutations. (a) A detailed list of EGFR mutations in each exon are shown in the below boxes. Different colors of each box represent different classes of mutations following structure-based classification. Ex20ins-L, exon 20 loop insertions; Ex20ins-NL, exon 20 near-loop insertions; Ex20ins-FL, exon 20 far-loop insertions; PACC, P-loop and αC-helix compressing mutations. (b) The sensitivity to EGFR TKIs of each group of mutations based on structure-based classification.
Biomolecules 13 00210 g004
Table
Table 1. EGFR TKIs currently in clinical use or in development for patients with EGFR-mutant NSCLC.
Table 1. EGFR TKIs currently in clinical use or in development for patients with EGFR-mutant NSCLC.
EGFR TKISelectivityBinding ModeStatus in NSCLC
1st-generationErlotinibWT EGFRReversibleFDA-approved
GefitinibWT EGFRReversibleFDA-approved
2nd-generationAfatinibWT EGFRIrreversibleFDA-approved
DacomitinibWT EGFRIrreversibleFDA-approved
3rd-generationOsimertinib (AZD9291)Mutant EGFRIrreversibleFDA-approved
Aumolertinib (HS-10296)Mutant EGFRIrreversibleApproved in China [55]
Alflutinib (AST2818)Mutant EGFRIrreversibleApproved in China [56]
4th-generationJBJ-09-063Mutant EGFRReversibleUnder investigation [59]
BLU-945Mutant EGFRReversibleUnder investigation [58]
Table
Table 2. Complex mutations identified in exon 18 from GENIE lung cancer dataset.
Table 2. Complex mutations identified in exon 18 from GENIE lung cancer dataset.
E709XPartner MutationCountG719XPartner MutationCount
E709AG719A12G719CS768I43
E709KG719A11G719AS768I24
E709AG719R8G719SS768I14
E709AG719C3G719AL861Q12
E709KG719S3G719SL861Q11
E709KG719C2G719AR776H6
E709VG719C2G719AL833V5
E709VG719S1G719SS768N3
E709AL861R1G719SR776H3
E709AL861Q1G719DL861Q2
Table
Table 3. Complex mutations identified in exon 20 and 21 from GENIE lung cancer dataset.
Table 3. Complex mutations identified in exon 20 and 21 from GENIE lung cancer dataset.
Ex20insPartner MutationCountL861XPartner MutationCount
N771_H773dupV845L2L861QS720F3
D770delinsEQPLH773Y1L861QS768I2
D770delinsELN771Y1L861RS768I1
D770_V774dupQ791E1L861RP1073T1
D770_P772dupH773Y1L861QR776H1
D770_N771insYS1030L1L861QR776C1
D770_N771insGN771Y1L861QL838V1
A767_V769dupR836C1L861QL833F1
A767_S768insQRGV765L1L861QL747F1
H773delinsQIN771H1
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Du, Z.; Sun, J.; Zhang, Y.; Hesilaiti, N.; Xia, Q.; Cui, H.; Fan, N.; Xu, X. Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer. Biomolecules 2023, 13, 210. https://doi.org/10.3390/biom13020210

AMA Style

Du Z, Sun J, Zhang Y, Hesilaiti N, Xia Q, Cui H, Fan N, Xu X. Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer. Biomolecules. 2023; 13(2):210. https://doi.org/10.3390/biom13020210

Chicago/Turabian Style

Du, Zhenfang, Jinghan Sun, Yunkai Zhang, Nigaerayi Hesilaiti, Qi Xia, Heqing Cui, Na Fan, and Xiaofang Xu. 2023. "Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer" Biomolecules 13, no. 2: 210. https://doi.org/10.3390/biom13020210

APA Style

Du, Z., Sun, J., Zhang, Y., Hesilaiti, N., Xia, Q., Cui, H., Fan, N., & Xu, X. (2023). Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer. Biomolecules, 13(2), 210. https://doi.org/10.3390/biom13020210

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop